Hub : Traits :

Forced expiratory volume in 1-second (FEV1), predicted

743 significantly associated models · 174 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	16273995	18074702	8	1	1.3e-12	8.8e-12	1.1e-01	94	MST1P9
2	1	40748755	42406344	2	1	5.5e-12	2.3e-11	7.3e-03	84	SCMH1
3	1	50735395	52135979	1	1	5.1e-09	9.1e-10	2.7e-02	87	CDKN2C
4	1	149672809	150515021	3	1	1.6e-09	6.2e-16	6.5e-08	55	RP11-196G18.22
5	1	183325796	184739300	1	1	5.1e-16	7.2e-16	6.8e-02	95	TSEN15
6	2	24348096	25837917	2	1	7.9e-09	2.1e-10	6.5e-06	50	ADCY3
7	2	55401562	56843605	1	1	9.3e-11	1.8e-13	2.3e-04	75	EFEMP1
8	2	168949234	170419444	2	1	1.2e-12	6.4e-11	1.6e-03	77	NOSTRIN
9	2	218827778	220226393	1	1	5.4e-08	5.1e-06	1.1e-01	87	BCS1L
10	2	231913056	233446568	3	2	2.6e-10	3.0e-08	7.0e-01	100	DIS3L2 PDE6D
11	3	49615624	50998816	1	1	9.3e-08	2.5e-07	6.8e-01	99	SEMA3B-AS1
12	3	56341514	56902096	1	1	2.0e-07	2.9e-06	5.2e-01	98	CCDC66
13	3	128788778	129284415	1	1	1.4e-07	1.3e-06	4.8e-02	83	H1FX
14	3	140350567	141867638	1	1	5.1e-30	6.1e-30	1.0e+00	100	ZBTB38
15	4	17104059	18507692	2	1	8.2e-27	6.6e-28	1.0e-05	84	DCAF16
16	4	145203531	146788825	2	2	9.4e-13	7.0e-23	4.8e-12	51	ANAPC10 OTUD4
17	5	130830617	132693330	8	1	5.3e-12	3.0e-09	1.0e+00	100	P4HA2
18	5	176040488	177260129	1	1	1.0e-12	3.4e-12	7.2e-03	85	RAB24
19	5	178968049	180374523	1	1	4.1e-08	8.4e-10	1.9e-03	74	MAPK9
20	6	7481928	8118906	1	1	3.3e-08	9.5e-13	4.0e-07	50	BMP6
21	6	33745071	36158878	9	7	3.2e-17	1.5e-19	NaN	NaN	C6orf106 RPL10A ZNF76
22	6	104478130	106230491	2	1	1.0e-10	1.2e-17	2.0e-08	57	LIN28B
23	6	125970401	127355237	1	1	8.9e-11	4.7e-12	1.6e-02	88	CENPW
24	6	129638583	131163098	2	1	2.4e-17	7.0e-16	1.0e+00	100	RP11-73O6.3
25	6	141924760	143855272	2	1	4.7e-17	1.8e-18	1.0e+00	100	GPR126
26	7	2032803	5003373	3	2	2.1e-15	2.5e-15	1.0e+00	100	GNA12 SDK1
27	7	23296533	23818538	1	1	1.2e-08	3.3e-09	1.2e-02	82	TRA2A
28	7	27623776	28468319	1	1	1.8e-10	2.1e-15	2.3e-06	64	JAZF1
29	7	91492103	93160671	2	1	4.2e-12	3.6e-14	8.4e-05	73	CDK6
30	8	130517157	131045893	1	1	3.8e-10	1.2e-10	7.7e-02	92	GSDMC
31	9	97573117	98969746	2	1	1.2e-09	1.2e-14	1.6e-11	24	RP11-435O5.5
32	9	138628816	140071683	2	1	4.0e-08	1.4e-07	8.1e-01	100	SEC16A
33	10	4334578	5844628	2	1	2.8e-09	7.2e-08	1.0e+00	100	AKR1C3
34	10	103527782	105275242	7	1	6.4e-11	2.7e-08	2.8e-01	96	TMEM180
35	11	66468469	67856510	1	1	2.3e-17	3.0e-17	1.0e+00	100	RAD9A
36	12	191619	1190134	1	1	1.8e-07	1.5e-07	9.6e-04	60	KDM5A
37	12	27587038	29432481	2	1	6.0e-13	1.4e-13	2.0e-02	90	CCDC91
38	12	55677395	57452308	7	1	1.9e-08	1.2e-07	9.8e-01	100	IL23A
39	13	49557805	51390447	2	2	2.2e-07	1.3e-12	2.8e-10	21	DLEU2 EBPL
40	14	91831899	93223990	1	1	1.1e-07	1.7e-07	1.0e+00	100	RP11-529H20.5
41	15	73524629	74915888	1	1	1.6e-07	2.6e-06	2.4e-04	39	LOXL1-AS1
42	15	84151637	85895721	11	1	7.6e-14	2.4e-15	1.0e-06	62	AC103965.1
43	15	89192873	89701439	1	1	2.1e-08	2.8e-12	2.1e-12	-1	MFGE8
44	15	99816860	101209341	1	1	1.5e-08	5.7e-10	7.1e-08	24	CTD-3076O17.1
45	16	1994980	2502641	2	1	4.1e-08	1.0e-06	2.8e-01	95	CASKIN1
46	16	89825065	90172696	1	1	9.4e-08	1.1e-05	1.8e-01	91	DBNDD1
47	17	6652789	8112253	3	1	3.4e-08	5.1e-08	1.8e-01	94	CHRNB1
48	17	17484654	18914778	1	1	1.9e-07	6.0e-07	6.3e-01	99	TOP3A
49	17	28398977	30034689	3	2	2.4e-11	4.2e-18	3.2e-06	71	CRLF3 RP11-848P1.7
50	17	59245274	59736794	1	1	5.6e-08	4.6e-09	2.5e-02	85	C17orf82
51	17	60916262	62694738	9	2	9.8e-13	9.8e-12	2.1e-01	97	DDX42 SCN4A
52	18	20082830	21806700	3	1	1.3e-10	2.2e-24	1.5e-16	34	RIOK3
53	18	45873080	47686517	1	1	1.0e-07	3.1e-07	8.7e-02	89	DYM
54	19	1916392	2466607	1	1	5.1e-08	3.1e-09	1.0e+00	100	DOT1L
55	19	19378671	19892796	2	1	6.3e-08	3.0e-06	6.7e-01	99	TSSK6
56	20	31382860	35512648	35	11	1.4e-27	3.7e-30	NaN	NaN	CEP250 E2F1 GDF5 GGT7 MMP24 TP53INP2 UQCC UQCC1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.6	3	1	2.2	0.00	1.0e+00	AC103965.1 TP53INP2 TSSK6
Bipolar Disorder or Schizophrenia	1.7	1	1	2.2	0.00	1.0e+00	AC103965.1
Depressed Affect (Nagel 2018)	1.3	1	0	0.0	0.00	1.0e+00	LOXL1-AS1
Intelligence (Savage-Jansen 2018)	1.4	5	1	2.2	0.99	2.0e-03	CENPW DCAF16 DDX42 DLEU2 RP11-435O5.5
Neuroticism (Nagel 2018)	1.6	4	2	4.4	-0.99	1.4e-02	CENPW LIN28B LOXL1-AS1 TP53INP2
Schizophrenia (2018)	1.4	2	1	2.2	0.00	1.0e+00	AC103965.1 LIN28B
Worry (Nagel 2018)	1.6	3	0	0.0	0.00	1.0e+00	CENPW TMEM180 TP53INP2
Crohns Disease (2017)	2.0	4	3	6.7	0.79	2.1e-01	ADCY3 P4HA2 SEC16A ZBTB38
Irritable Bowel Disease (IBD)	1.8	4	2	4.4	0.65	3.5e-01	ADCY3 GNA12 P4HA2 SEC16A
Ulcerative Colitis (UC)	1.8	3	2	4.4	0.00	1.0e+00	GNA12 MMP24 SEC16A
Reaction Time	1.4	1	0	0.0	0.00	1.0e+00	TMEM180
Verbal and Numeric Reasoning (VNR)	1.5	2	1	2.2	0.00	1.0e+00	CENPW DCAF16
Breast Cancer	2.3	6	5	11.1	-0.54	2.7e-01	ADCY3 P4HA2 RP11-196G18.22 RP11-73O6.3 RP11-848P1.7 ZBTB38
Prostate Cancer	1.9	1	0	0.0	0.00	1.0e+00	TMEM180
Body Mass Index (BMI) (2010)	1.6	1	0	0.0	0.00	1.0e+00	ADCY3
Coronary Artery Disease (CAD)	2.0	1	0	0.0	0.00	1.0e+00	C6orf106
Crohns Disease (2012)	1.5	1	1	2.2	0.00	1.0e+00	P4HA2
Fasting Glucose	1.4	1	1	2.2	0.00	1.0e+00	NOSTRIN
HDL Cholesterol	1.9	1	1	2.2	0.00	1.0e+00	C6orf106
LDL Cholesterol	2.0	1	1	2.2	0.00	1.0e+00	C6orf106
Lupus	1.6	1	0	0.0	0.00	1.0e+00	ZNF76
Rheumatoid Arthritis	1.5	1	0	0.0	0.00	1.0e+00	CDK6
Schizophrenia (2014)	1.3	2	1	2.2	0.00	1.0e+00	AC103965.1 LIN28B
Triglycerides	1.2	1	0	0.0	0.00	1.0e+00	TP53INP2
Type 2 Diabetes (T2D) (2012)	2.1	1	1	2.2	0.00	1.0e+00	JAZF1
Ulcerative Colitis	2.1	2	1	2.2	0.00	1.0e+00	GNA12 SEC16A
Blood Eosinophil Count	2.3	14	6	13.3	-0.35	2.2e-01	AC103965.1 CDK6 CRLF3 DLEU2 GNA12 JAZF1 NOSTRIN P4HA2 RAB24 RP11-73O6.3 RPL10A SEC16A SEMA3B-AS1 ZNF76
Blood Platelet Count	2.0	17	13	28.9	-0.81	1.8e-05	AC103965.1 BCS1L C6orf106 CDK6 CRLF3 DCAF16 DDX42 DYM E2F1 GNA12 OTUD4 P4HA2 RIOK3 RP11-848P1.7 SCMH1 TMEM180 TSSK6
Blood Red Count	1.8	16	10	22.2	0.01	9.5e-01	AC103965.1 BCS1L C17orf82 C6orf106 CENPW DOT1L E2F1 GPR126 IL23A RAD9A RP11-435O5.5 RP11-73O6.3 SEC16A SEMA3B-AS1 TSSK6 ZBTB38
Blood White Count	2.2	21	13	28.9	-0.40	7.0e-02	BCS1L C6orf106 CASKIN1 CDK6 CENPW DCAF16 DDX42 EBPL GGT7 GNA12 NOSTRIN P4HA2 RIOK3 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SEC16A TMEM180 TRA2A ZNF76
Heel T-Score	3.8	37	28	62.2	-0.67	4.2e-06	ADCY3 ANAPC10 BMP6 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL GGT7 GNA12 GPR126 GSDMC H1FX LIN28B MST1P9 PDE6D RAB24 RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RPL10A SCMH1 UQCC1 ZBTB38 ZNF76
BMI	2.7	19	11	24.4	-0.15	5.0e-01	ADCY3 C17orf82 C6orf106 CASKIN1 CHRNB1 DCAF16 DDX42 DIS3L2 DYM GPR126 GSDMC JAZF1 LOXL1-AS1 MST1P9 OTUD4 RAB24 RIOK3 RP11-73O6.3 TSSK6
Height	30.4	70	70	155.6	0.98	6.5e-52	AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 KDM5A LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Waist Hip Ratio (WHR)	4.8	28	21	46.7	-0.24	1.9e-01	AC103965.1 ADCY3 AKR1C3 ANAPC10 C17orf82 C6orf106 CENPW CEP250 CHRNB1 DLEU2 DOT1L DYM EBPL GDF5 H1FX JAZF1 MST1P9 OTUD4 RAB24 RAD9A RIOK3 RP11-529H20.5 RP11-73O6.3 SCN4A TOP3A UQCC UQCC1 ZBTB38
Systolic Blood Pressure	2.0	14	6	13.3	0.13	6.3e-01	ADCY3 BMP6 C17orf82 CDK6 CEP250 DCAF16 EFEMP1 GDF5 GPR126 JAZF1 RPL10A SCMH1 SEMA3B-AS1 UQCC
Smoking Status	1.4	2	0	0.0	0.00	1.0e+00	C6orf106 TMEM180
Allergy or Eczema	2.4	7	3	6.7	-0.03	9.3e-01	C6orf106 CCDC66 GNA12 JAZF1 P4HA2 TMEM180 ZBTB38
Cardiovascular Disease	1.6	7	2	4.4	-0.55	2.0e-01	C17orf82 C6orf106 CDK6 CRLF3 DCAF16 RIOK3 ZNF76
Respiratory disease	1.7	2	2	4.4	0.00	1.0e+00	P4HA2 ZNF76
Type 2 Diabetes (T2D) (2018)	2.0	2	1	2.2	0.00	1.0e+00	CENPW JAZF1
Lung FEV1/FVC ratio	6.3	24	15	33.3	0.00	9.9e-01	AC103965.1 ADCY3 C6orf106 CDKN2C CENPW CEP250 EFEMP1 GDF5 GGT7 GNA12 GPR126 LOXL1-AS1 MMP24 MST1P9 OTUD4 P4HA2 RP11-435O5.5 RPL10A TOP3A TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Lung FVC	6.4	39	30	66.7	-0.41	6.5e-03	ANAPC10 BMP6 C17orf82 C6orf106 CCDC91 CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DOT1L EBPL EFEMP1 GDF5 GSDMC JAZF1 LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 PDE6D RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Neuroticism	1.4	4	0	0.0	-0.99	1.0e-02	CENPW LIN28B TMEM180 TP53INP2
Chronotype (morning person)	1.4	2	1	2.2	0.00	1.0e+00	SEC16A SEMA3B-AS1
Hair Pigment	12.2	17	12	26.7	-0.44	5.4e-02	ADCY3 CENPW CEP250 DBNDD1 E2F1 GDF5 GGT7 JAZF1 MMP24 RP11-196G18.22 RP11-73O6.3 SEC16A TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Tanning	15.0	11	10	22.2	0.69	6.4e-03	ADCY3 CEP250 DBNDD1 E2F1 GDF5 GGT7 JAZF1 MMP24 TP53INP2 UQCC UQCC1
Hand grip strength (left)	8.1	27	17	37.8	0.97	6.7e-18	ADCY3 BCS1L BMP6 CASKIN1 CEP250 CHRNB1 DCAF16 DOT1L DYM GDF5 GGT7 H1FX LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 RAD9A RP11-73O6.3 SCN4A TMEM180 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Number of treatments/medications taken	1.6	3	0	0.0	0.00	1.0e+00	C6orf106 DCAF16 LIN28B
Relative age of first facial hair	3.3	7	4	8.9	0.28	4.7e-01	C6orf106 DBNDD1 LIN28B SCMH1 SEMA3B-AS1 UQCC ZBTB38
Systolic blood pressure, automated reading	1.8	6	2	4.4	-0.77	7.2e-02	ADCY3 C17orf82 CDK6 DCAF16 EFEMP1 RPL10A
Medication: Metformin	1.9	1	1	2.2	0.00	1.0e+00	JAZF1
Impedance of leg (right)	4.1	27	14	31.1	-0.20	2.7e-01	AC103965.1 ADCY3 BCS1L C6orf106 CDK6 CEP250 CTD-3076O17.1 E2F1 GDF5 GSDMC H1FX JAZF1 LIN28B MMP24 MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCMH1 SCN4A SEMA3B-AS1 TOP3A TP53INP2 UQCC UQCC1
Leg fat-free mass (left)	16.4	58	45	100.0	0.95	3.3e-33	AKR1C3 ANAPC10 BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Trunk fat percentage	3.4	15	10	22.2	0.74	6.2e-04	AC103965.1 ADCY3 C6orf106 CASKIN1 CENPW CTD-3076O17.1 EFEMP1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RPL10A ZBTB38
Hand grip strength (right)	9.4	32	19	42.2	0.96	5.7e-20	ADCY3 AKR1C3 BCS1L BMP6 C6orf106 CASKIN1 CEP250 CHRNB1 DCAF16 DDX42 DOT1L DYM E2F1 GDF5 GGT7 H1FX LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 RAD9A RP11-73O6.3 SCMH1 SCN4A TMEM180 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Relative age voice broke	3.2	4	1	2.2	-0.55	2.6e-01	GDF5 LIN28B SCMH1 UQCC
Age when periods started (menarche)	3.9	5	3	6.7	0.34	5.8e-01	ADCY3 CENPW LIN28B SCMH1 SEMA3B-AS1
Heel bone mineral density (BMD) T-score, automated (left)	2.0	5	2	4.4	-0.98	2.2e-03	CDK6 DLEU2 EBPL LIN28B RP11-435O5.5
High blood pressure	1.4	4	0	0.0	-0.74	2.6e-01	C17orf82 C6orf106 DCAF16 P4HA2
Hayfever, allergic rhinitis or eczema	2.1	5	2	4.4	-0.21	6.1e-01	C6orf106 CCDC66 P4HA2 TMEM180 ZBTB38
Sitting height	25.5	63	60	133.3	0.93	5.3e-32	AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Body mass index (BMI)	2.5	11	3	6.7	-0.02	9.5e-01	ADCY3 C17orf82 C6orf106 DCAF16 DDX42 DIS3L2 JAZF1 OTUD4 RIOK3 RP11-73O6.3 TSSK6
Impedance of leg (left)	4.0	25	13	28.9	-0.19	3.3e-01	AC103965.1 ADCY3 BCS1L C6orf106 CDK6 CEP250 CTD-3076O17.1 E2F1 GDF5 GPR126 H1FX JAZF1 LIN28B MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCN4A SEMA3B-AS1 TOP3A TP53INP2 UQCC UQCC1
Leg predicted mass (left)	16.4	57	45	100.0	0.95	4.5e-33	AKR1C3 ANAPC10 BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Trunk fat mass	6.5	29	23	51.1	0.91	3.6e-14	AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CDK6 CEP250 CTD-3076O17.1 DBNDD1 E2F1 EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX LIN28B MFGE8 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RP11-848P1.7 RPL10A TSEN15 UQCC UQCC1 ZBTB38
Waist circumference	3.8	15	10	22.2	0.81	5.2e-05	AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-848P1.7 RPL10A TSSK6 ZBTB38
Past tobacco smoking	1.7	1	0	0.0	0.00	1.0e+00	TMEM180
Alcohol usually taken with meals	1.3	1	0	0.0	0.00	1.0e+00	CHRNB1
Nervous feelings	1.7	2	0	0.0	0.00	1.0e+00	CENPW TP53INP2
Hearing difficulty/problems with background noise	1.2	2	0	0.0	0.00	1.0e+00	LIN28B TMEM180
Hair/balding pattern: Pattern 2	1.7	1	0	0.0	0.00	1.0e+00	CENPW
Had menopause	1.5	1	0	0.0	0.00	1.0e+00	RP11-73O6.3
Forced vital capacity (FVC)	11.9	48	35	77.8	0.93	1.8e-24	AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CCDC66 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MST1P9 NOSTRIN OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right)	2.1	5	1	2.2	-0.95	1.1e-02	CDK6 DLEU2 EBPL RP11-435O5.5 ZBTB38
Qualifications: None of the above	1.7	2	0	0.0	0.00	1.0e+00	CENPW UQCC1
Allergy	2.3	8	3	6.7	0.00	9.9e-01	C6orf106 CCDC66 GNA12 JAZF1 P4HA2 SEMA3B-AS1 TMEM180 ZBTB38
Diabetes (self-reported)	2.0	3	1	2.2	0.00	1.0e+00	AKR1C3 JAZF1 SEC16A
Medication: Ramipril	1.4	1	0	0.0	0.00	1.0e+00	C6orf106
Fluid intelligence score	1.5	2	0	0.0	0.00	1.0e+00	DCAF16 RP11-435O5.5
Neuroticism score	1.1	1	0	0.0	0.00	1.0e+00	TP53INP2
Weight	12.0	49	38	84.4	0.95	3.9e-29	AC103965.1 ANAPC10 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DLEU2 DOT1L E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX MFGE8 MMP24 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38
Impedance of arm (right)	3.7	20	13	28.9	0.23	3.1e-01	AC103965.1 C6orf106 CASKIN1 CENPW CEP250 CTD-3076O17.1 E2F1 EFEMP1 GPR126 JAZF1 LIN28B LOXL1-AS1 MFGE8 MST1P9 RP11-196G18.22 RP11-529H20.5 RP11-73O6.3 SCMH1 TP53INP2 TSSK6
Arm fat percentage (right)	2.5	12	6	13.3	-0.16	5.7e-01	ADCY3 C17orf82 C6orf106 CENPW CHRNB1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 SCN4A ZNF76
Trunk fat-free mass	21.8	62	59	131.1	0.96	1.5e-38	ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Hip circumference	8.4	36	26	57.8	0.92	9.6e-19	AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CCDC66 CDK6 CDKN2C CEP250 CRLF3 DBNDD1 DLEU2 DOT1L E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX NOSTRIN OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38
Worrier / anxious feelings	1.2	1	0	0.0	0.00	1.0e+00	TMEM180
Frequency of tiredness / lethargy in last 2 weeks	1.5	1	0	0.0	0.00	1.0e+00	GGT7
Hair/balding pattern: Pattern 3	2.0	1	1	2.2	0.00	1.0e+00	CENPW
Forced expiratory volume in 1-second (FEV1)	9.4	41	27	60.0	0.94	4.0e-22	AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX LOXL1-AS1 MAPK9 MFGE8 MST1P9 NOSTRIN OTUD4 P4HA2 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A UQCC ZBTB38 ZNF76
Pulse rate	1.4	1	1	2.2	0.00	1.0e+00	ZBTB38
Qualifications: A levels/AS levels or equivalent	1.9	5	0	0.0	0.97	1.5e-03	CHRNB1 DCAF16 GDF5 UQCC UQCC1
Mouth/teeth dental problems: Dentures	1.2	1	0	0.0	0.00	1.0e+00	TP53INP2
Asthma	2.0	2	2	4.4	0.00	1.0e+00	P4HA2 ZNF76
Illnesses of mother	1.3	1	0	0.0	0.00	1.0e+00	DCAF16
Forced expiratory volume in 1-second (FEV1), Best measure	9.3	39	27	60.0	0.94	1.5e-21	AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DCAF16 DDX42 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 OTUD4 P4HA2 RAB24 RAD9A RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A UQCC ZBTB38 ZNF76
Impedance of arm (left)	3.8	21	13	28.9	0.38	9.1e-02	AC103965.1 C6orf106 CENPW CTD-3076O17.1 E2F1 EFEMP1 GNA12 GPR126 JAZF1 LIN28B LOXL1-AS1 MFGE8 MST1P9 RAD9A RIOK3 RP11-196G18.22 RP11-529H20.5 RP11-73O6.3 SCMH1 TP53INP2 TSSK6
Arm fat mass (right)	3.8	16	13	28.9	0.82	4.7e-06	ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GDF5 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC ZBTB38
Trunk predicted mass	21.8	63	60	133.3	0.96	1.2e-38	ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Standing height	29.9	70	70	155.6	0.98	1.7e-53	AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 KDM5A LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Tense / 'highly strung'	1.3	2	0	0.0	0.00	1.0e+00	RP11-196G18.22 TP53INP2
Hair/balding pattern: Pattern 4	2.2	3	2	4.4	0.00	1.0e+00	CDKN2C CENPW ZBTB38
Birth weight of first child	2.8	6	3	6.7	0.94	4.6e-03	ANAPC10 DCAF16 OTUD4 RP11-73O6.3 ZBTB38 ZNF76
Peak expiratory flow (PEF)	6.8	25	14	31.1	0.98	3.8e-20	ADCY3 ANAPC10 C6orf106 CDKN2C CEP250 DCAF16 DLEU2 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX LOXL1-AS1 MMP24 NOSTRIN OTUD4 RAD9A RP11-73O6.3 RPL10A SCN4A TMEM180 UQCC UQCC1 ZNF76
Pulse wave reflection index	1.5	1	0	0.0	0.00	1.0e+00	TSSK6
Blood clot in the leg (DVT)	1.8	3	0	0.0	0.00	1.0e+00	E2F1 MMP24 TP53INP2
Birth weight	4.1	12	5	11.1	0.85	5.1e-04	ANAPC10 CDK6 CENPW CRLF3 DCAF16 GDF5 GNA12 GPR126 RP11-435O5.5 RP11-73O6.3 TRA2A ZNF76
Chronic bronchitis/emphysema (mother)	2.0	1	0	0.0	0.00	1.0e+00	DBNDD1
Forced vital capacity (FVC), Best measure	11.8	48	36	80.0	0.94	6.1e-25	AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CCDC66 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Body fat percentage	2.8	14	7	15.6	0.30	2.6e-01	AC103965.1 ADCY3 C6orf106 CASKIN1 CENPW CHRNB1 CTD-3076O17.1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 ZBTB38 ZNF76
Leg fat percentage (right)	3.1	14	11	24.4	-0.42	9.1e-02	AC103965.1 ADCY3 C6orf106 CENPW CEP250 DCAF16 DDX42 GDF5 MMP24 RIOK3 RP11-435O5.5 SCN4A TSSK6 UQCC
Arm fat-free mass (right)	18.4	57	52	115.6	0.96	5.4e-36	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Comparative body size at age 10	3.5	7	2	4.4	-0.66	1.1e-01	ADCY3 DBNDD1 DIS3L2 DOT1L LIN28B RP11-529H20.5 TP53INP2
Worry too long after embarrassment	1.6	1	0	0.0	0.00	1.0e+00	TP53INP2
Number of children fathered	1.3	1	0	0.0	0.00	1.0e+00	IL23A
Age at first live birth	1.2	1	0	0.0	0.00	1.0e+00	DCAF16
Qualifications: College or University degree	1.5	6	0	0.0	0.75	5.2e-02	CENPW DDX42 GDF5 RIOK3 UQCC UQCC1
Mouth/teeth dental problems: Loose teeth	1.3	1	1	2.2	0.00	1.0e+00	CCDC91
Medication for pain relief, constipation, heartburn	1.8	1	0	0.0	0.00	1.0e+00	C6orf106
Medication: Omeprazole	1.8	1	0	0.0	0.00	1.0e+00	C6orf106
Medication: Seretide 50 evohaler	1.1	1	0	0.0	0.00	1.0e+00	P4HA2
Mean time to correctly identify matches	1.3	2	0	0.0	0.00	1.0e+00	CCDC66 RP11-73O6.3
Whole body fat mass	5.2	24	18	40.0	0.88	1.5e-10	AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CDK6 CEP250 CTD-3076O17.1 E2F1 EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC UQCC1 ZBTB38
Leg fat mass (right)	3.7	15	11	24.4	0.78	1.2e-04	AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-73O6.3 RPL10A TSSK6 ZBTB38
Arm predicted mass (right)	18.3	57	52	115.6	0.96	8.6e-36	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Pulse rate, automated reading	1.5	4	2	4.4	0.41	4.2e-01	C6orf106 CHRNB1 JAZF1 ZBTB38
Alcohol intake frequency.	1.0	2	1	2.2	0.00	1.0e+00	RIOK3 TOP3A
Comparative height size at age 10	25.4	66	63	140.0	0.97	4.3e-44	AC103965.1 ADCY3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 KDM5A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Overall health rating	1.8	2	1	2.2	-0.78	2.2e-01	C6orf106 DCAF16
Family relationship satisfaction	1.1	1	0	0.0	0.00	1.0e+00	RP11-73O6.3
Knee pain experienced in last month	4.0	3	3	6.7	-0.99	5.8e-04	CEP250 GDF5 UQCC
Hypertension (Self-reported)	1.4	4	0	0.0	-0.72	2.8e-01	C17orf82 C6orf106 DCAF16 P4HA2
Illnesses of father: Heart disease	1.5	1	0	0.0	0.00	1.0e+00	GGT7
Whole body fat-free mass	20.0	62	54	120.0	0.95	2.9e-36	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg fat-free mass (right)	16.7	59	46	102.2	0.95	6.3e-33	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Arm fat percentage (left)	2.6	12	7	15.6	-0.14	6.3e-01	ADCY3 C17orf82 C6orf106 CENPW CHRNB1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 SCN4A ZNF76
Average weekly red wine intake	1.6	1	0	0.0	0.00	1.0e+00	RIOK3
Diabetes diagnosed by doctor	2.1	2	1	2.2	0.00	1.0e+00	CENPW JAZF1
Medication for cholesterol	1.9	1	0	0.0	0.00	1.0e+00	C6orf106
Back pain experienced in last month	1.8	1	0	0.0	0.00	1.0e+00	C6orf106
Breast cancer (self-reported)	1.4	1	0	0.0	0.00	1.0e+00	CDKN2C
Asthma (self-reported)	1.9	3	2	4.4	0.00	1.0e+00	P4HA2 ZBTB38 ZNF76
Medication: Gliclazide	1.5	1	0	0.0	0.00	1.0e+00	JAZF1
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.9	8	2	4.4	-0.51	2.0e-01	BMP6 CCDC91 GDF5 GPR126 JAZF1 RPL10A UQCC ZNF76
Whole body water mass	19.6	61	54	120.0	0.95	5.3e-36	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg predicted mass (right)	16.6	58	46	102.2	0.95	4.9e-33	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Arm fat mass (left)	3.9	16	13	28.9	0.82	5.1e-06	ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GDF5 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC ZBTB38
Number of self-reported non-cancer illnesses	1.5	1	0	0.0	0.00	1.0e+00	P4HA2
Miserableness	1.1	1	0	0.0	0.00	1.0e+00	LOXL1-AS1
Guilty feelings	1.4	1	1	2.2	0.00	1.0e+00	LIN28B
Commuting to job workplace: Public transport	1.0	1	0	0.0	0.00	1.0e+00	SEMA3B-AS1
Medication: Blood pressure	1.7	2	2	4.4	0.00	1.0e+00	C6orf106 P4HA2
High cholesterol (Self-reported)	1.6	1	0	0.0	0.00	1.0e+00	DCAF16
Medication: Bendroflumethiazide	1.3	1	0	0.0	0.00	1.0e+00	P4HA2
Ever smoked	1.1	1	0	0.0	0.00	1.0e+00	TMEM180
Basal metabolic rate	18.4	63	51	113.3	0.95	6.9e-36	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg fat percentage (left)	3.1	15	10	22.2	-0.44	6.8e-02	AC103965.1 ADCY3 C6orf106 CENPW CEP250 DCAF16 DDX42 GDF5 MMP24 RIOK3 RP11-435O5.5 SCN4A TSSK6 UQCC ZNF76
Arm fat-free mass (left)	17.9	57	51	113.3	0.96	3.4e-35	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Number of operations (self-reported)	1.9	2	0	0.0	0.00	1.0e+00	GNA12 LIN28B
Irritability	1.4	2	1	2.2	0.00	1.0e+00	RP11-73O6.3 TP53INP2
Ever had prostate specific antigen (PSA) test	1.5	1	0	0.0	0.00	1.0e+00	ZBTB38
Diastolic blood pressure, automated reading	1.5	6	1	2.2	-0.81	4.8e-02	ADCY3 C17orf82 DCAF16 P4HA2 SCMH1 ZNF76
Myopia	1.9	1	0	0.0	0.00	1.0e+00	C6orf106
Vascular/heart problems diagnosed by doctor	1.6	4	2	4.4	0.73	2.7e-01	C17orf82 C6orf106 DCAF16 P4HA2
Cholesterol lowering medication	1.6	1	0	0.0	0.00	1.0e+00	DDX42
Pain experienced in last month	1.6	1	0	0.0	0.00	1.0e+00	CENPW
Basal cell carcinoma (self-reported)	1.8	2	0	0.0	0.00	1.0e+00	DBNDD1 TP53INP2
Deep venous thrombosis (DVT) (self-reported)	1.8	4	0	0.0	0.66	3.4e-01	CHRNB1 E2F1 MMP24 TP53INP2
Impedance of whole body	3.9	25	20	44.4	-0.03	8.8e-01	AC103965.1 ADCY3 C6orf106 CENPW CEP250 CTD-3076O17.1 E2F1 EFEMP1 GDF5 GPR126 JAZF1 LIN28B MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCMH1 SCN4A SEMA3B-AS1 TOP3A TP53INP2 TSSK6 UQCC
Leg fat mass (left)	3.8	15	10	22.2	0.78	1.2e-04	AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-73O6.3 RPL10A TSSK6 ZBTB38
Arm predicted mass (left)	17.8	57	51	113.3	0.96	6.5e-35	AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	22	0.63	2.3
GTEx	Adipose Visceral Omentum	9	0.44	2.2
GTEx	Adrenal Gland	6	0.41	2.1
GTEx	Artery Aorta	16	0.54	2.2
GTEx	Artery Coronary	4	0.34	2.1
GTEx	Artery Tibial	27	0.72	2.3
GTEx	Brain Caudate basal ganglia	2	0.22	2.0
GTEx	Brain Cerebellar Hemisphere	6	0.40	2.1
GTEx	Brain Cerebellum	10	0.50	2.2
GTEx	Brain Cortex	6	0.58	2.3
GTEx	Brain Frontal Cortex BA9	4	0.43	2.1
GTEx	Brain Hippocampus	2	0.38	2.3
GTEx	Brain Hypothalamus	5	0.85	2.2
GTEx	Brain Nucleus accumbens basal ganglia	5	0.58	2.2
GTEx	Brain Putamen basal ganglia	4	0.64	2.1
GTEx	Breast Mammary Tissue	11	0.56	2.1
GTEx	Breast Mammary Tissue (Male)	10	0.84	2.3
GTEx	Breast Mammary Tissue (Female)	7	0.43	2.1
GTEx	Cells EBV-transformed lymphocytes	10	0.70	2.2
GTEx	Cells Transformed fibroblasts	15	0.36	2.1
GTEx	Colon Sigmoid	5	0.34	2.2
GTEx	Colon Transverse	13	0.63	2.2
GTEx	Esophagus Gastroesophageal Junction	7	0.48	2.1
GTEx	Esophagus Mucosa	26	0.78	2.2
GTEx	Esophagus Muscularis	17	0.53	2.2
GTEx	Heart Atrial Appendage	11	0.70	2.2
GTEx	Heart Left Ventricle	4	0.26	2.0
GTEx	Liver	3	0.42	2.1
GTEx	Lung	17	0.59	2.2
GTEx	Muscle Skeletal	17	0.59	2.2
GTEx	Nerve Tibial	28	0.65	2.2
GTEx	Ovary	4	0.44	2.3
GTEx	Pancreas	11	0.67	2.2
GTEx	Pituitary	10	0.90	2.3
GTEx	Prostate	2	0.24	2.1
GTEx	Skin Not Sun Exposed Suprapubic	15	0.61	2.1
GTEx	Skin Sun Exposed Lower leg	21	0.58	2.2
GTEx	Small Intestine Terminal Ileum	2	0.43	2.1
GTEx	Spleen	7	0.50	2.2
GTEx	Stomach	11	0.76	2.1
GTEx	Testis	21	0.67	2.3
GTEx	Thyroid	23	0.58	2.2
GTEx	Uterus	0	0.00	2.0
GTEx	Vagina	1	0.16	1.8
GTEx	Whole Blood	9	0.45	2.2
METSIM	Adipose	17	0.37	2.0
NTR	Blood	10	0.42	2.0
ROSMAP	Brain Pre-frontal Cortex	18	0.41	2.1
YFS	Blood	17	0.37	1.9
CommonMind	Brain Pre-frontal Cortex	23	0.43	2.0
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	2.0
The Cancer Genome Atlas	Breast Invasive Carcinoma	17	0.39	2.0
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.27	1.9
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.39	2.1
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.58	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.29	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	12	0.44	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	15	0.37	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	6	0.29	2.0
The Cancer Genome Atlas	Brain Lower Grade Glioma	20	0.46	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	6	0.54	2.0
The Cancer Genome Atlas	Lung Adenocarcinoma	13	0.44	1.9
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	1.9
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.25	2.0
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.18	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.30	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	21	0.45	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.00	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	2.1
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.9
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.12	2.0
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.23	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	21	0.41	1.9
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	4	0.79	2.1